Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

Both parties will also expand research and development efforts. National Taiwan University Hospital (NTUH) and AbbVie ...

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...

This was the stock's third consecutive day of losses.

AbbVie Inc (ABBV) stock saw a decline, ending the day at $179.53 which represents a decrease of $-0.57 or -0.32% from the prior close of $180.1. The stock opened at $179.63 and touched a low of ...

Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...

Merck just rewarded its shareholders again with a dividend hike. This Dow stock has come with a quarterly dividend for almost ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on AbbVie (ABBV – Research Report) yesterday and set a price target of ...

Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 5 years ago, it would be worth $2,015.83 today based on a ...

This was the stock's second consecutive day of losses.

In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...